$17M to AI startup focused on medical research recruiting

A healthcare AI startup whose product scours EMRs to quickly find qualified patients for clinical trials has raised $17 million in Series A funding.

Pasadena, Calif.-based Deep 6 AI announced the round Nov. 25, saying the capital will go toward building its capacity to meet growing demand for not only speedy research participant recruitment but also systematic study design and project management.

In the announcement, the company said more than 85% of clinical trials registered with the FDA get delayed or canceled due to inadequate patient participation.

“We see clinical trials recruiting as a place where a data and AI-driven approach holds tremendous promise in accelerating life-saving research,” added Daniel Gwak, a partner in one of the investment firms leading the funding round, Point72 Ventures. Gwak will join Deep 6 AI’s board of directors as part of the deal.

Deep 6 AI says its current customer roster already includes numerous large healthcare providers, including Cedars Sinai Medical Center and Texas Medical Center, along with various life-sciences companies, contract research organizations and makers of medical devices.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.